PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70386 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Jiezuo Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Neoplasms, Epigenesis, Genetic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Natural Science Foundation of Changsha Municipal.
Abstract (Originalsprache)
The family of protein arginine methyltransferases (PRMTs) occupies an important position in biology, especially during the initiation and development of cancer. PRMT3 and CARM1(also known as PRMT4), being type I protein arginine methyltransferases, are key in controlling tumour progression by catalysing the mono‐methylation and asymmetric di‐methylation of both histone and non‐histone substrates. This paper reviews the functions and potential therapeutic target value of PRMT3 and CARM1 in a variety of cancers. Studies have identified abnormal expressions of PRMT3 and CARM1 in several malignancies, closely linked to cancer progression, advancement, and resistance to treatment. Such as hepatocellular carcinoma, colorectal cancer, ovarian cancer, and endometrial cancer. These findings offer new strategies and directions for cancer treatment, especially in enhancing the effectiveness of conventional treatment methods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Xiangya College of Public Health, Central South University, Changsha, China.
- Hunan Normal University School of Medicine, Changsha, China.
- Department of Gynaecology and Obstetrics, Second Xiangya Hospital, Central South University, Changsha, China.
- NHC Key Laboratory of Carcinogenesis and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, School of Basic Medical Science, Central South Universit…
ORCID-Profile: Fenghe Li
Förderung
- The Natural Science Foundation of Changsha Municipal
Zitieren
APA
Huang, J., Qiao, B., Yuan, Y., Xie, Y., Xia, X., Li, F., & Wang, L. (2025). PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70386
Vancouver
Huang J, Qiao B, Yuan Y, Xie Y, Xia X, Li F, et al. PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70386
BibTeX
@article{Huang2025,
author = {Huang, Jiezuo and Qiao, Beining and Yuan, Yixin and Xie, Yuxuan and Xia, Xiaomeng and Li, Fenghe and Wang, Lei},
title = {PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70386}
}
EUVIMED